SCHEMBL498271

SCHEMBL498271

CCCCOc1cc(C=O)ccc1C(=O)OC

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
MAPT P10636 5/20 0.65
HPGD P15428 3/20 0.65
CYP2C9 P11712 2/20 0.65
HSP90AA1 P07900 2/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2C19 P33261 1/20 0.65
FDPS P14324 1/20 0.51
NPSR1 Q6W5P4 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12636175 0.91 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL27031322 0.84 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL7537944 0.83 TSHR (0.55) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL16482859 0.82 MAOA (0.54) ALDH1A1SMN1; SMN2MAPTHPGDHSP90AA1
SCHEMBL28487405 0.82 NPC1 (0.58) ALDH1A1HPGDCYP2C9FDPSNPSR1
SCHEMBL359439 0.82 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL20415948 0.81 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL498071 0.81 HTT (0.63) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9
SCHEMBL4307363 0.81 HDAC3 (0.57) ALDH1A1MAPTHPGDCYP2C9HSP90AA1
SCHEMBL30834674 0.80 FDPS (0.67) ALDH1A1SMN1; SMN2MAPTHPGDCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-7846960-B2 FXR agonists ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-2029547-B1 FXR AGONISTS LILLY CO ELI (US) 2010-04-28 EP disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090270460-A1 FXR AGONISTS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-10-29 US disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed
EP-2029547-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
EP-2029558-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed
WO-2007140174-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270460-A1 FXR AGONISTS NR1H4, SLC10A1, GPBAR1 ALDH1A1 2072/4885SMN1; SMN2 4695/4885MAPT 3995/4885
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 ALDH1A1 2294/4885SMN1; SMN2 4859/4885MAPT 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.